CRANBURY, N.J., Nov. 21, 2016 /PRNewswire/ --
WHAT: CPI-613 is Cornerstone Pharmaceuticals' lead drug
candidate, a first-in-class anticancer compound designed to disrupt
the altered energy production pathways in cancer cells by targeting
mitochondrial metabolism. It selectively targets the mitochondrial
tricarboxylic acid (TCA) cycle, a process essential to tumor cell
proliferation and survival. The two datasets are from the first
reported studies of CPI-613-based combination therapies in patients
with AML and T-cell NHL.
ASH Abstract Details:
- TCA Cycle Inhibition by CPI-613 Increases Sensitivity to
Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia
(AML)
- Date/Time: Monday, December 5,
2016 6:00-8:00 PM PT
- Session: 616. Acute Myeloid Leukemia: Novel Therapy,
Excluding Transplantation: Poster III
- Location: San Diego
Convention Center, Hall GH
- Abstract #: 4062
- Scheduled Presenter: Timothy S.
Pardee, M.D. Ph.D., Section on Hematology and Oncology,
Comprehensive Cancer Center of Wake Forest Baptist Medical Center,
Winston-Salem,
N
- Phase I Dose-Escalation Study of CPI-613, in Combination
with Bendamustine, in Relapsed or Refractory T-Cell Non-Hodgkin
Lymphoma
- Date/Time: Monday, December 5,
2016, 6:00-8:00 PM PT
- Session: 624. Hodgkin Lymphoma and T/NK Cell
Lymphoma—Clinical Studies: Poster III
- Location: San Diego
Convention Center, Hall GH
- Abstract #: 4163
- Scheduled Presenter: Zanetta S.
Lamar, M.D., Department of Hematology / Oncology, Wake
Forest Baptist Medical Center, Winston-Salem, NC
WHO: Drs. Pardee and Lamar (primary investigators) will
be available for media interviews upon request
WHERE: American Society of Hematology Annual Meeting,
San Diego Convention Center,
San Diego, California
CONTACT: Kara Golub,
609-456-0822 or kgolub@jfkhealth.com, for more information.
About Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. is a privately held,
clinical-stage, oncology-focused pharmaceutical company committed
to the development and commercialization of therapies that exploit
the metabolic differences between normal cells and cancer cells.
The company's investors include IDT Corporation (NYSE: IDT).
Cornerstone's primary objective is to develop highly selective and
effective agents with minimal toxic effects on normal cells and
tissues. Cornerstone's first-in-class clinical lead compound,
CPI-613 is being evaluated in multiple Phase I, I/II, and II
clinical studies. The U.S. Food and Drug Administration (FDA) has
designated CPI-613 an orphan drug for the treatment of acute
myeloid leukemia (AML), pancreatic cancer and myelodysplastic
syndromes (MDS).www.cornerstonepharma.com.
Safe Harbor Statement
This press release contains forward-looking statements. These
statements relate to future events or the company's future
financial performance. In some cases, you can identify
forward-looking statements by terminology such as "may", "will",
"should", "expect", "plan", "anticipate", "believe", "estimate",
"predict", "potential" or "continue", the negative of such terms,
or other comparable terminology. These statements are only
predictions. Actual events or results may differ materially from
those in the forward-looking statements as a result of various
important factors. Although we believe that the expectations
reflected in the forward-looking statements are reasonable, such
statements should not be regarded as a representation by the
company, or any other person, that such forward looking statements
will be achieved. The business and operations of the company are
subject to substantial risks which increase the uncertainty
inherent in forward-looking statements. We undertake no duty to
update any of the forward-looking statements, whether as a result
of new information, future events or otherwise. In light of the
foregoing, readers are cautioned not to place undue reliance on
such forward-looking statements.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cornerstone-pharmaceuticals-to-present-new-data-on-cpi-613-at-the-american-society-of-hematology-2016-annual-meeting-300366293.html
SOURCE Cornerstone Pharmaceuticals